Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland.
Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland.
Bioorg Med Chem Lett. 2019 Aug 15;29(16):2316-2319. doi: 10.1016/j.bmcl.2019.06.022. Epub 2019 Jun 18.
The YAP-TEAD protein-protein interaction is a potential therapeutic target to treat cancers in which the Hippo signaling pathway is deregulated. However, the extremely large surface of interaction between the two proteins presents a formidable challenge for a small molecule interaction disrupter approach. We have accomplished progress towards showing the feasibility of this approach by the identification of a 15-mer peptide able to potently (nanomolar range) disrupt the YAP-TEAD interaction by targeting only one of the two important sites of interaction. This peptide, incorporating non-natural amino acids selected by structure-based design, is derived from the Ω-loop sequence 85-99 of YAP.
YAP-TEAD 蛋白-蛋白相互作用是治疗 Hippo 信号通路失调的癌症的潜在治疗靶点。然而,两个蛋白质之间的相互作用的表面积非常大,这给小分子相互作用破坏剂的方法带来了巨大的挑战。我们通过鉴定一种 15 肽来证明这种方法的可行性,该肽能够通过仅靶向两个重要相互作用位点之一来有效地(纳摩尔范围)破坏 YAP-TEAD 相互作用。该肽由基于结构设计选择的非天然氨基酸组成,来源于 YAP 的 Ω 环序列 85-99。